Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T28484
|
||||
Former ID |
TTDC00143
|
||||
Target Name |
Kinesin-like protein KIF11
|
||||
Gene Name |
KIF11
|
||||
Synonyms |
Eg5; Kinesin-like protein 1; Kinesin-like spindle protein HKSP; Kinesin-related motor protein Eg5; TRIP5; Thyroid receptor interacting protein 5; KIF11
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Acute myeloid leukemia [ICD9: 205; ICD10: C92.0] | ||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Hematological malignancies [ICD9: 200-209; ICD10: C81-C86] | |||||
Head and neck cancer; Renal cell carcinoma; Ovarian cancer; Solid tumors [ICD9: 140-149, 140-199, 140-229, 183, 189, 210-229; ICD10: C07-C14, C32-C33, C56, C64, D10-D36, D3A] | |||||
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Function |
Motor protein required for establishing a bipolar spindle. Blocking of KIF11 prevents centrosome migration and arrest cells in mitosis with monoastral microtubule arrays.
|
||||
BioChemical Class |
Kinesin-like protein family
|
||||
Target Validation |
T28484
|
||||
UniProt ID | |||||
Sequence |
MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADK
SSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERS PNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLEIYNEELFDLLNPSSDVSE RLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAYSSRSHSVFS VTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVIT ALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNIL NKPEVNQKLTKKALIKEYTEEIERLKRDLAAAREKNGVYISEENFRVMSGKLTVQEEQIV ELIEKIGAVEEELNRVTELFMDNKNELDQCKSDLQNKTQELETTQKHLQETKLQLVKEEY ITSALESTEEKLHDAASKLLNTVEETTKDVSGLHSKLDRKKAVDQHNAEAQDIFGKNLNS LFNNMEELIKDGSSKQKAMLEVHKTLFGNLLSSSVSALDTITTVALGSLTSIPENVSTHV SQIFNMILKEQSLAAESKTVLQELINVLKTDLLSSLEMILSPTVVSILKINSQLKHIFKT SLTVADKIEDQKKELDGFLSILCNNLHELQENTICSLVESQKQCGNLTEDLKTIKQTHSQ ELCKLMNLWTERFCALEEKCENIQKPLSSVQENIQQKSKDIVNKMTFHSQKFCADSDGFS QELRNFNQEGTKLVEESVKHSDKLNGNLEKISQETEQRCESLNTRTVYFSEQWVSSLNER EQELHNLLEVVSQCCEASSSDITEKSDGRKAAHEKQHNIFLDQMTIDEDKLIAQNLELNE TIKIGLTKLNCFLEQDLKLDIPTGTTPQRKSYLYPSTLVRTEPREHLLDQLKRKQPELLM MLNCSENNKEETIPDVDVEEAVLGQYTEEPLSQEPSVDAGVDCSSIGGVPFFQHKKSHGK DKENRGINTLERSKVEETTEHLVTKSRLPLRAQINL |
||||
Structure |
1II6; 1Q0B; 1X88; 1YRS; 2FKY; 2FL2; 2FL6; 2FME; 2G1Q; 2GM1; 2IEH; 2PG2; 2Q2Y; 2Q2Z; 2UYI; 2UYM; 2WOG; 2X2R; 2X7C; 2X7D; 2X7E; 2XAE; 3CJO; 3HQD; 3K3B; 3K5E; 3KEN; 3L9H; 3ZCW; 4A1Z; 4A28; 4A50; 4A51; 4A5Y; 4AP0; 4AQV; 4AQW; 4AS7; 4B7B; 4BBG; 4BXN; 4CK5; 4CK6; 4CK7; 1II6; 1Q0B; 1X88; 1YRS; 2FKY; 2FL2; 2FL6; 2FME; 2G1Q; 2GM1; 2IEH; 2PG2; 2Q2Y; 2Q2Z; 2UYI; 2UYM; 2WOG; 2X2R; 2X7C; 2X7D; 2X7E; 2XAE; 3CJO; 3HQD; 3K3B; 3K5E; 3KEN; 3L9H; 3ZCW; 4A1Z; 4A28; 4A50; 4A51; 4A5Y; 4AP0; 4AQV; 4AQW; 4AS7; 4B7B;4BBG; 4BXN; 4CK5; 4CK6; 4CK7
|
||||
Drugs and Mode of Action | |||||
Drug(s) | ARRY-520 | Drug Info | Phase 2 | Cancer | [524532] |
AZD-4877 | Drug Info | Phase 2 | Acute myeloid leukemia | [522297], [542683] | |
Ispinesib | Drug Info | Phase 2 | Head and neck cancer; Renal cell carcinoma; Ovarian cancer; Solid tumors | [521617] | |
LY2523355 | Drug Info | Phase 2 | Acute myeloid leukemia | [523589] | |
SB-743921 | Drug Info | Phase 2 | Cancer | [521846], [530907] | |
4SC-205 | Drug Info | Phase 1 | Lymphoma | [551497] | |
ARQ 621 | Drug Info | Phase 1 | Hematological malignancies | [522550] | |
MK-0731 | Drug Info | Phase 1 | Solid tumours | [521631] | |
Inhibitor | 4SC-205 | Drug Info | [551497] | ||
Adenosine-5'-Diphosphate | Drug Info | [551391] | |||
ARRY-520 | Drug Info | [536588], [537357] | |||
AZD-4877 | Drug Info | [531974] | |||
Ispinesib | Drug Info | [536879], [537505], [537526] | |||
MK-0731 | Drug Info | [531974] | |||
Monastrol | Drug Info | [551393] | |||
SB-743921 | Drug Info | [537212] | |||
Modulator | ARQ 621 | Drug Info | [531974] | ||
LY2523355 | Drug Info | [531974] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
Reactome | MHC class II antigen presentation | ||||
Kinesins | |||||
WikiPathways | MHC class II antigen presentation | ||||
Kinesins | |||||
References | |||||
Ref 521617 | ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health. | ||||
Ref 521631 | ClinicalTrials.gov (NCT00104364) A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED). U.S. National Institutes of Health. | ||||
Ref 521846 | ClinicalTrials.gov (NCT00343564) A Study of SB-743921 in Non-Hodgkin's Lymphoma. U.S. National Institutes of Health. | ||||
Ref 522297 | ClinicalTrials.gov (NCT00661609) A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer. U.S. National Institutes of Health. | ||||
Ref 522550 | ClinicalTrials.gov (NCT00825487) Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies. U.S. National Institutes of Health. | ||||
Ref 523589 | ClinicalTrials.gov (NCT01416389) A Study of LY2523355 in Patients With Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 524532 | ClinicalTrials.gov (NCT01989325) A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma. U.S. National Institutes of Health. | ||||
Ref 530907 | A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol. 2011 Feb;67(2):447-54. | ||||
Ref 536879 | Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. | ||||
Ref 537357 | Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 May 21. | ||||
Ref 537505 | KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain? BMC Cancer. 2009 Jun 22;9:196. | ||||
Ref 537526 | Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Jun 24. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.